India to Iraq: Actinomycin Export Trade Route

To import Actinomycin formulations into Iraq, the following approvals and registrations are necessary:

• Product Registration: All pharmaceutical products, including Actinomycin formulations, must be registered with the Technical Affairs Directorate of the Iraqi Ministry of Health. The registration process involves submitting a comprehensive dossier that aligns with international standards, including the Common Technical Document (CTD) format.

• Dossier Requirements: The submission should include:
• A Certificate of Pharmaceutical Product (CPP) from the country of origin.
• Clinical study results for new chemical entities (NCEs).
• Bioequivalence and bioavailability data for generic drugs.
• Specifications and accompanying documentation in line with international reference or WHO standards.

• Timelines: Decisions on drug applications are mandated to be made within one year, emphasizing the importance of forward planning for market entry.

• Registration Validity: For imported products, the registration is valid for five years.

• Fees: Specific product registration fees are not detailed in the available information.

• GMP Inspection Requirements: The Ministry of Health reserves the right to conduct inspections to ensure Good Manufacturing Practice (GMP) compliance if deemed necessary.

Indian manufacturers exporting Actinomycin formulations to Iraq must comply with the following GMP standards:

• GMP Certification: Manufacturers are required to adhere to the updated Schedule M of the Drugs and Cosmetics Act, which aligns with WHO-GMP standards. This includes stringent quality controls across manufacturing processes to enhance drug safety and prevent adulteration.

• Compliance Deadline: As of December 31, 2025, all pharmaceutical companies, including Micro, Small, and Medium Enterprises (MSMEs), must fully comply with the revised Schedule M requirements. Non-compliance may result in closure of operations.

• Inspection and Enforcement: State drug regulators in India have been directed to enforce these standards rigorously. For instance, in November 2025, Delhi's drug regulator initiated inspections and issued warning closure notices to non-compliant firms, mandating upgrades by the December 31, 2025 deadline.

• Recent Regulatory Actions: In December 2024, the FDA inspected an Indian manufacturer and found severe GMP violations, including unsanitary conditions and inadequate quality systems. This led to a recall of products and an import ban into the USA.

Several regulatory changes and policy shifts have occurred between 2024 and 2026, impacting Indian pharmaceutical exports to Iraq:

• Revised Schedule M Implementation: In December 2023, the Ministry of Health and Family Welfare updated Schedule M to align with WHO-GMP standards. This amendment mandates stronger quality controls across manufacturing processes.

• Compliance Deadlines: While larger pharmaceutical companies were required to comply within six months, MSMEs were granted an extension until December 31, 2025, provided they submitted an upgrade plan by May 11, 2025.

• Enforcement Actions: By November 2025, state drug regulators, including those in Delhi, Himachal Pradesh, and Uttarakhand, began issuing warning notices and conducting inspections to ensure compliance with the updated GMP standards. Non-compliant firms faced potential closure if they failed to upgrade by the December 31, 2025 deadline.

These developments underscore the critical importance for Indian exporters to Iraq to ensure full compliance with the updated GMP standards to maintain market access and uphold product quality.

Actinomycin, particularly Dactinomycin, is utilized in oncology treatments. The global Dactinomycin market was valued at $200 million in 2024 and is projected to grow to $300 million by 2035, with a compound annual growth rate (CAGR) of 2.6% from 2025 to 2035. While specific data for Iraq is limited, the country's oncology drugs market is expected to reach $120 million in 2025, reflecting an 8.1% revenue change from the previous year. This growth is driven by an increasing prevalence of cancer, enhanced healthcare infrastructure, and rising demand for effective oncology treatments.

Iraq's pharmaceutical market is projected to generate $1.72 billion in revenue in 2025, with a per capita revenue of $36.21. The market is characterized by a mix of imports and domestic manufacturing, with imports playing a significant role in meeting the country's pharmaceutical needs.

Iraq imposes a uniform import tariff of 5% on pharmaceutical products under HS code 30049046. This rate applies to most imports, with exemptions for specific categories such as food, medicine, books, clothing, and products related to humanitarian assistance or Iraq’s reconstruction. Additionally, projects initiated through the National Investment Commission (NIC) or established in a Free Zone may be exempt from this tariff for a period determined by import classification.

As of November 2021, Iraq's import tariffs based on the Harmonized Classification System range from zero to 30 percent, with many products subject to a uniform tariff of 5%. There is no specific Free Trade Agreement (FTA) between India and Iraq affecting pharmaceutical tariffs, and no anti-dumping duties have been reported for Actinomycin formulations.

India is a key supplier of finished pharmaceutical formulations containing Actinomycin to Iraq, accounting for 0.7% of India's total Actinomycin formulation exports, valued at $2.9 million. The top Indian exporters include Chandra Bhagat Pharma Limited, Ravi Pharma, Distinct Impex Private Limited, and Seatrack International Tradex Private Limited. The primary buyers in Iraq are entities such as "To the Order," Skin Line Logistic, and Zahra.

While specific data on other major countries supplying Actinomycin to Iraq is limited, India's established pharmaceutical industry and competitive pricing position it as a significant player in the Iraqi market. India's pricing for Actinomycin formulations is generally competitive compared to manufacturers from China and the European Union, contributing to its substantial share in Iraq's pharmaceutical imports.

India is a global leader in generic pharmaceutical production, accounting for approximately 20% of the global supply by volume as of 2024. The country boasts a robust manufacturing infrastructure with 752 FDA-approved sites, 2,050 WHO-GMP certified plants, and 286 EDQM-approved facilities, the highest globally. This extensive network includes specialized facilities dedicated to the production of finished dosage forms containing Actinomycin, such as tablets, capsules, and injections.

The cost structure of Indian pharmaceutical manufacturing is highly competitive, attributed to economies of scale, a skilled workforce, and efficient supply chains. These factors enable Indian manufacturers to offer Actinomycin formulations at prices significantly lower than those from other regions, without compromising on quality. Additionally, the presence of numerous WHO-GMP and FDA-approved facilities ensures that products meet stringent international quality standards, making India a preferred source for Actinomycin formulations globally.

When comparing Actinomycin formulation exports, India offers a compelling balance of cost and quality. In 2024, India exported medicaments of other antibiotics, not for retail, to Iraq valued at $160.70K for 2,303 kg, resulting in an average price of approximately $69.80 per kg. In contrast, the European Union exported similar products valued at $196.57K for 5,854 kg, averaging about $33.58 per kg. While the EU's per-unit cost appears lower, Indian formulations are often preferred due to their adherence to international quality standards and cost-effectiveness.

China's exports of similar products to Iraq in 2024 were valued at $711.52K for 161,800 kg, averaging approximately $4.40 per kg. Despite the lower cost, concerns regarding quality perception and regulatory acceptance in Iraq may influence buyers' preferences. Indian manufacturers have a strong track record of regulatory compliance and supply reliability, making them a favorable choice for Actinomycin formulations.

The India-Iraq Actinomycin formulation supply chain is characterized by robust manufacturing capacity and reliable supply channels. Indian facilities are equipped with advanced packaging and cold chain capabilities essential for maintaining the integrity of Actinomycin formulations during transit. Notably, in November 2025, Granules India Limited's subsidiary, Granules Life Sciences Private Limited, received U.S. FDA approval for its Hyderabad facility, enhancing its finished dosage manufacturing capabilities.

While some Indian manufacturers have faced regulatory challenges, such as Sun Pharma's Halol facility being placed under FDA Import Alert in September 2025, these issues are being addressed through corrective actions and investments in new facilities. Overall, Indian manufacturers continue to expand their capacities and maintain a strong compliance track record, ensuring a reliable supply of Actinomycin formulations to Iraq.

For Iraqi buyers sourcing Actinomycin formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply chain.

• Minimum Order Quantities (MOQs): Negotiate MOQs that align with your demand forecasts to optimize inventory levels and reduce holding costs.

• Payment Terms: Familiarize yourself with common payment terms in India-Iraq pharmaceutical trade, such as Letters of Credit (LC) or advance payments, to facilitate smooth transactions.

• Supplier Qualification Process: Implement a rigorous supplier qualification process, including audits of manufacturing facilities, verification of regulatory approvals, and assessment of quality control systems.

• Regulatory Compliance: Ensure that selected suppliers have a strong track record of regulatory compliance and can provide necessary documentation for product registration in Iraq.

By adopting these strategies, Iraqi buyers can establish a reliable and cost-effective supply chain for Actinomycin formulations from India.

1. Verify Manufacturer Registration with Iraqi DRA: Confirm that the Indian manufacturer is registered with the Iraqi Drug Regulatory Authority (DRA). This registration is mandatory for all pharmaceutical companies intending to supply products to Iraq.

2. Assess GMP Certification Validity: Obtain and review the manufacturer's Good Manufacturing Practice (GMP) certificate. Ensure it is current and issued by a recognized authority such as the U.S. FDA, EMA, or WHO. The Iraqi DRA recognizes certifications from these bodies, potentially exempting the manufacturer from additional inspections.

3. Review Drug Master File (DMF): Request the DMF for the Actinomycin formulation. This document provides comprehensive information on the manufacturing process, controls, and specifications, ensuring the product's quality and safety.

4. Evaluate Quality Management System (QMS): Ensure the manufacturer has a robust QMS in place, compliant with international standards like ISO 9001:2015. A strong QMS indicates the manufacturer's commitment to consistent product quality and continuous improvement.

5. Confirm Product Registration in Iraq: Verify that the specific Actinomycin formulation is registered with the Iraqi DRA. Unregistered products cannot be legally imported or distributed within Iraq.

6. Assess Regulatory History: Investigate the manufacturer's regulatory history for any past violations, warning letters, or import alerts. A clean history suggests compliance with international standards.

7. Conduct Risk Assessment: Perform a risk assessment considering factors such as product complexity, supply chain criticality, and regulatory compliance. This assessment helps determine the level of scrutiny required during the qualification process.

1. Certificate of Analysis (CoA): Details the specific results of laboratory testing for a particular batch, confirming it meets predefined specifications.

2. Certificate of Origin (CoO): Certifies the country where the product was manufactured, essential for customs and regulatory purposes.

3. GMP Certificate: Issued by a recognized regulatory authority, this certificate confirms the manufacturer complies with GMP standards, ensuring product quality and safety.

4. Stability Data: Provides evidence of the product's shelf life under various environmental conditions, ensuring it remains effective throughout its intended duration.

5. Batch Records: Comprehensive documentation of the production process for each batch, ensuring traceability and consistency.

6. Drug Master File (DMF): Contains detailed information about the manufacturing process, controls, and specifications of the drug product.

7. Free Sale Certificate: Indicates that the product is legally sold in the country of origin, suggesting it meets the regulatory standards of that country.

8. Insurance Certificates: Proof of liability insurance coverage, providing assurance against potential product-related risks.

1. Regulatory Non-Compliance: Presence of recent warning letters, import alerts, or GMP suspensions from authorities like the U.S. FDA or WHO indicates potential compliance issues.

2. Unusually Low Pricing: Prices significantly below market rates may suggest compromised quality or substandard manufacturing practices.

3. Lack of Stability Data: Inability to provide comprehensive stability data raises concerns about the product's shelf life and efficacy.

4. Limited Export History: Absence of a track record in exporting to regulated markets may indicate inexperience or potential compliance gaps.

5. Resistance to Audits: Hesitation or refusal to allow facility audits suggests potential issues with transparency or compliance.

1. Pre-Audit Desktop Review: Before an on-site visit, review all available documentation, including GMP certificates, previous audit reports, and quality manuals.

3. Post-Audit Corrective Actions: Document any deficiencies found during the audit and require the manufacturer to implement corrective and preventive actions within a specified timeframe.

4. Annual Re-Qualification: Conduct annual audits to ensure ongoing compliance and address any new risks or changes in the manufacturing process.

5. Remote Monitoring Options: Utilize technology for virtual audits, document reviews, and regular communication to maintain oversight between physical audits.

6. Cost Estimates and Timeline: Budget approximately $5,000 to $10,000 for an on-site audit, including travel and accommodation. Plan for a timeline of 4-6 weeks from scheduling to completion of the audit report.

By meticulously following these guidelines, Iraqi pharmaceutical companies can establish reliable partnerships with Indian Actinomycin manufacturers, ensuring the delivery of high-quality and compliant products to the Iraqi market.